US-based bioprocessing technology developer GPB Scientific has raised $25.5m in funding yesterday from investors including Amgen Ventures, the corporate venturing arm of pharmaceutical firm Amgen.
Growth equity firm Vensana Capital led the round, which also featured undisclosed existing investors. The company had previously received $3.8m in equity funding and $2.4m in debt financing between 2014 and September 2019 according to regulatory filings.
GPB is developing microfluidics (fluid manipulation) technology based on its proprietary cell processing system, for use in therapeutics and disease diagnostic systems, in partnership with universities and research institutes.
Philip Tagari, vice-president of therapeutic discovery for Amgen, said: “As the industry works to implement reliable, efficient and cost-effective systems for the global deployment of these breakthrough medical treatments, GPB has devised an elegant yet powerful solution for cell separation, washing and concentration.
“The broad potential of this innovation aligns with Amgen’s mission to partner with innovators in the fight against serious illness.”
